Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics Study of TAS-102 in Refractory Metastatic Colorectal Cancer
jRCT2080221873Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC), colon adenocarcinoma and rectal adenocarcinoma comparing TAS-102 with Placebo (2 arms).
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2080221873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221873.